PhD student in Epidemiology
Award-winning publication: Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
Published in: The Lancet Infectious Diseases. 12(10), 781-789. Paru en octobre 2012
"Cervarix and Gardasil, the two human papilloma virus (HPV) vaccines, protect against the strains that lead to over two-thirds of cases of cervical cancer. Clinical trials indicate that the efficacy of the vaccines against precancerous lesions linked to HPV is almost perfect and even suggest that the vaccines provide cross-protection against the other types of HPV that lead to 20% of cancers, but which are not included in the vaccines. I carried out the first systematic review of clinical data on the cross-protection of HPV vaccines and rigorously compared them to data on populations naïve to the infection. The meta-analysis suggests that the vaccines' cross-protection differs: Cervarix provides greater cross-protection that however weakens in longer clinical trials."
Talia Malagon's study was decisive for the public health decision-makers in Québec and Canada tasked with selecting the vaccine to use in vaccination programs. The differences in cross-protection could decrease the number of cases of cervical cancer and therefore constitute an important factor to consider when choosing a vaccine. The results of the study were used by researchers in Canada, the United States and Europe and helped assess the eventual impact of vaccination on the incidence of HPV-related cancers and the cost-effectiveness of vaccination strategies.